Biohaven (BHVN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.78
- Estimate
- -$0.61
- Surprise
- -27.6%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Biohaven (BHVN) reported a wider loss than forecast — adjusted EPS of -$0.78 against the -$0.61 estimate (a 27.6% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates BHVN Sell at 5.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -27.6% surprise compares with a -143.6% four-quarter average. Next scheduled report: 2027-03-01.
What argues against it
- Quality below floor (2.1 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $15.61
- Price target
- $21.24
- Stop
- $14.52
- Upside to target
- +36.1%
- Reward-to-risk
- 2.4:1
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
BHVN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.29B
- P/E (fwd)
- -8.1
- 52-week range
- $7.48–$18.24
- Off 52-week high
- 14.4%
- RSI (14)
- 73
- Volume vs avg
- 0.54×
- Score today
- 5.5/10